S5D:4 Low vitamin d is associated with thrombosis in systemic lupus erythematosus. (21st March 2018)

• Record Type: Journal Article
• Authors: Petri, M; Fu, W; Goldman, D
• Is Part Of: Lupus science & medicine. Volume 5(2018)Supplement 1
• Page Start: A18
• Page End: A19
• Publication Date: 2018-03-21
• Subjects: Vitamin D -- Thrombosis; Systemic lupus erythematosus -- Periodicals; 616.772005
• DOI: 10.1136/lupus-2018-abstract.30
• Languages: English
• ISSNs: 2398-8851

Abstract

Abstract : Background/purpose: Low vitamin D is common in systemic lupus erythematosus (SLE). It is also found in antiphospholipid syndrome. Vitamin D has effects on tissue factor, PAI-1, thrombomodulin and platelet aggregation that suggest it has an anti-thrombotic role. We asked whether low vitamin D was associated with thrombosis in SLE, adjusting for lupus anticoagulant. Methods: A total of 1, 392 SLE patients were included in the analysis. At the first visit when vitamin D was measured, 76.7% had levels of 25-hydroxyvitamin D<40 ng/mL. The SLE patients were: 92% female, mean age 42.9 years, and ethnicity 50% Caucasian, 41% African American. 27% patients had a history of thrombosis; 7% stroke, 4% MI and 14% DVT. Results: Vitamin D, measured either as a continuous variable or as 'low' (<40 ng/mL) vs normal, was associated with any thrombosis and with DVT. We next looked prospectively: this analysis excluded thrombotic events before the first vitamin D measurement. It allowed for vitamin D to be a time-varying variable, as replacement therapy was given if it was low. After adjustment for race, age and sex, the adjusted hazard ratio remained significant for any thrombosis: 1.75 (1.04, 2.92). Conclusion: Low vitamin D was significantly associated with any thrombosis and with DVT (even after adjustment for lupus anticoagulant). In prospective models it remained significantly associated with any thrombosis. As supplementation with vitamin D was proven to reduce thrombosis in an oncology randomised clinical trial, vitamin D replacement should become routine in SLE patients at risk for thrombosis.